Kalaris Therapeutics
KLRS
51 hedge funds and large institutions have $152M invested in Kalaris Therapeutics in 2025 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 5 closing their positions.
380% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 5
99% more capital invested
Capital invested by funds: $76.4M → $152M (+$75.5M)
59% more funds holding
Funds holding: 32 → 51 (+19)
43% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 7
25.52% more ownership
Funds ownership: 70.7% → 96.22% (+26%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$9.59M |
| 2 |
RI
RTW Investments
New York
|
+$8.31M |
| 3 |
PBA
Paradigm Biocapital Advisors
New York
|
+$4.48M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$2.58M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
+$2.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$2.42M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$902K |
| 3 |
Renaissance Technologies
New York
|
-$160K |
| 4 |
Millennium Management
New York
|
-$144K |
| 5 |
Squarepoint
New York
|
-$94.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Citigroup
New York
| $8 | – | – | – |
|
|
TCM
52
Tang Capital Management
San Diego,
California
| – | -$2.42M | -418,241 | Closed |
|
|
53
Millennium Management
New York
| – | -$144K | -24,923 | Closed |
|
54
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$3.34K | -578 | Closed |
|
|
SFCL
55
Strengthening Families & Communities LLC
Boston,
Massachusetts
| – | -$1.55K | -268 | Closed |
|
|
FFA
56
Farther Finance Advisors
San Francisco,
California
| – | -$191 | -33 | Closed |
|
KLRS Hedge Fund Activity: Q4 2025 in Review
51 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q4 2025, worth a combined $152M — up 99% from $76.4M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new KLRS positions and 5 closed out — a net gain of 19 holders — while 10 added to existing stakes and 7 trimmed.
The largest buyer was Samsara BioCapital, adding an estimated $9.59M. The largest seller was Tang Capital Management, exiting entirely with an estimated $2.42M sold.
- 51 institutional investors held Kalaris Therapeutics (KLRS) as of Q4 2025, up from 32 in Q3 2025.
- Funds reported $152M of Kalaris Therapeutics stock for Q4 2025, up 99% quarter-over-quarter.
- 24 funds opened new Kalaris Therapeutics positions in Q4 2025 and 5 closed out, a net change of +19 holders.
- The largest Kalaris Therapeutics buyer in Q4 2025 was Samsara BioCapital, an estimated $9.59M added.
- The largest Kalaris Therapeutics seller in Q4 2025 was Tang Capital Management, an estimated $2.42M sold.
Based on aggregated 13F filings for Q4 2025.